KIT and cancer: In contrast to VEGFRs, expression of KIT, FGFR1, FGFR2, FGFR4 and PDGFRA (additional targets of a small-molecule tyrosine kinase inhibitor lenvatinib associated with oncogenesis and maintenance of the tumor microenvironment in several types of cancer) was largely elevated among ACC tumors analyzed in this study.